FDA Grants Breakthrough Status to Raludotatug Deruxtecan for CDH6-Expressing Ovarian and Gynecologic Cancers
Raludotatug deruxtecan has received FDA Breakthrough Therapy Designation for treating CDH6-expressing platinum-resistant ovarian, peritoneal, or fallopian tube cancers, based on promising early trial data, marking a significant step in developing new treatments for these difficult-to-treat cancers.